Ameriprise
UTMD icon

Ameriprise’s Utah Medical Products UTMD Stock Holding History

Ameriprise’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$494K Buy
7,158
+58
+0.8% +$3.85K ﹤0.01% 3671
2026
Q1 		$440K Sell
7,100
-6,300
-47% -$397K ﹤0.01% 3638
2025
Q4 		$750K Hold
13,400
– – ﹤0.01% 3460
2025
Q3 		$844K Sell
13,400
-4,400
-25% -$260K ﹤0.01% 3441
2025
Q2 		$1.01M Sell
17,800
-150
-0.8% -$8.16K ﹤0.01% 3260
2025
Q1 		$1.01M Buy
17,950
+5,898
+49% +$353K ﹤0.01% 3204
2024
Q4 		$741K Sell
12,052
-2
-0% -$129 ﹤0.01% 3376
2024
Q3 		$807K Buy
12,054
+7,450
+162% +$506K ﹤0.01% 3305
2024
Q2 		$308K Hold
4,604
– – ﹤0.01% 3581
2024
Q1 		$327K Buy
+4,604
New +$345K ﹤0.01% 3558
2014
Q4 		– Sell
-12
Closed -$1K – 4390
2014
Q3 		$1K Buy
+12
New +$609 ﹤0.01% 5582
2013
Q4 		– Sell
-206
Closed -$12K – 5418
2013
Q3 		$12K Hold
206
– – ﹤0.01% 4781
2013
Q2 		$11K Buy
+206
New +$9.7K ﹤0.01% 4721

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's UTMD Position: Q2 2026 in Review

Ameriprise increased its Utah Medical Products (UTMD) stake by 0.82% in Q2 2026, buying an estimated $3.85K and bringing the position to 7,158 shares worth $494K. The position accounts for ﹤0.01% of the portfolio, ranked #3671.

Ameriprise first reported a position in UTMD in Q2 2013 and has held it in 13 quarters since. The position peaked at $1.01M in Q2 2025. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Ameriprise held 7,158 shares of Utah Medical Products worth $494K as of Q2 2026.
  • Ameriprise bought 58 Utah Medical Products shares in Q2 2026, an estimated $3.85K.
  • Utah Medical Products made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3671 holding.
  • Ameriprise first reported a position in Utah Medical Products in Q2 2013 and has held it in 13 quarters since.
  • Ameriprise's Utah Medical Products position peaked at $1.01M in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.